tasimelteon   Click here for help

GtoPdb Ligand ID: 7393

Synonyms: BMS-214778 | Hetlioz® | VEC-162
Approved drug
tasimelteon is an approved drug (FDA (2014), EMA (2015))
Compound class: Synthetic organic
Comment: Tasimelteon is a melatonin receptor agonist, activating both the MT1 and MT2 receptor subtypes equipotently. Ramelteon and agomelatine are also melatonin receptor agonist class drugs.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 1
Rotatable bonds 5
Topological polar surface area 38.33
Molecular weight 245.14
XLogP 1.84
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES CCC(=O)NCC1CC1c1cccc2c1CCO2
Isomeric SMILES CCC(=O)NC[C@@H]1C[C@H]1c1cccc2c1CCO2
InChI InChI=1S/C15H19NO2/c1-2-15(17)16-9-10-8-13(10)11-4-3-5-14-12(11)6-7-18-14/h3-5,10,13H,2,6-9H2,1H3,(H,16,17)/t10-,13+/m0/s1
No information available.
Summary of Clinical Use Click here for help
Approved to treat blind patients suffering from non-24-hour sleep–wake disorder. In the EU, the EMA has granted this drug orphan designation for the treatment of non-24-hour sleep-wake disorder.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Tasimelteon is a selective agonist for the melatonin MT1 and MT2 receptors. This drug effectively improves the onset and maintenance of sleep in blind patients who suffer from circadian rhythm sleep disorders due to an absence of photic input.
External links Click here for help